Given these concerns and other methodological questions regarding the appropriate comparator interventions and outcome measures, CMS considers the evidence inadequate to conclude that use of abarelix in patients with less severe prostate cancer than those with advanced disease described in the FDA-approved indication is as safe or as effective as currently available alternative therapies for this